Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Reviewing Maze Therapeutics' Topline Data from the Phase 2 HORIZON Trial of MZE829 in Patients with Broad APOL1-Mediated Kidney Disease

Ticker(s): MAZE, VRTX, AZN, LLY, JNJ, Boehringer Ingelheim

Who's the expert?

Institution: University of Iowa

Clinical Professor of Internal Medicine - Nephrology, and Medical Director for dialysis at University of Iowa
Currently manages 30+ patients with focal segmental glomerulosclerosis and 200 patients for potassium management
Research interests in IgA neuropathy, renal transplantation outcomes, and kidney dialysis

Interview Goal

The goal of this interview with a nephrologist is to discuss the Phase 2 HORIZON trial of MZE829 in APOL1-mediated kidney disease and its potential fit within the current treatment landscape.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.